Mugglestone C J, Swinhoe J R, Craft I L
Acta Obstet Gynecol Scand. 1980;59(4):327-9. doi: 10.3109/00016348009154089.
A single-blind pilot study using combined estrogen and progestogen therapy was undertaken in 25 patients for a period of six months in an attempt to evaluate symptomatic control, the acceptability or otherwise of bleeding patterns, and the effect on endometrial pathology. Two different progestogens were employed, i.e. norgestrel and norethisterone acetate, and each was given in combination with estradiol valerate in a cyclical and a continuous regime. Symptomatic control was good in all groups, but there was a mild recrudescence of some symptoms during the tablet-free interval in the cyclical groups. Regular withdrawal bleeding was reported in almost all cases receiving cyclical therapy, and unscheduled bleeding was noted in those on continuous regimes. Endometrial hyperplasia did not occur following treatment in any of the groups, and there was a return to the normal histology in two patients in whom hyperplasia existed prior to treatment. These results support the view that endometrial hyperplasia is least likely to occur if progestogens are administered in combination with estrogen. There were no obvious differences between the effects of the two progestogens.
对25例患者进行了一项为期6个月的单盲试点研究，采用雌激素和孕激素联合治疗，旨在评估症状控制情况、出血模式的可接受性或其他方面，以及对子宫内膜病理学的影响。使用了两种不同的孕激素，即炔诺孕酮和醋酸炔诺酮，每种都与戊酸雌二醇联合，采用周期性和连续性给药方案。所有组的症状控制良好，但在周期性给药组的停药间隔期间，一些症状有轻度复发。几乎所有接受周期性治疗的病例都报告有规律的撤退性出血，而接受连续性给药方案的患者则出现了不规则出血。治疗后，所有组均未发生子宫内膜增生，两名治疗前存在增生的患者恢复了正常组织学。这些结果支持这样一种观点，即孕激素与雌激素联合使用时，子宫内膜增生最不可能发生。两种孕激素的效果没有明显差异。
